BR112015029491A2 - derivados de imidazopirrolidinona e seu uso no tratamento de doença - Google Patents
derivados de imidazopirrolidinona e seu uso no tratamento de doençaInfo
- Publication number
- BR112015029491A2 BR112015029491A2 BR112015029491A BR112015029491A BR112015029491A2 BR 112015029491 A2 BR112015029491 A2 BR 112015029491A2 BR 112015029491 A BR112015029491 A BR 112015029491A BR 112015029491 A BR112015029491 A BR 112015029491A BR 112015029491 A2 BR112015029491 A2 BR 112015029491A2
- Authority
- BR
- Brazil
- Prior art keywords
- disease
- treatment
- imidazopyrrolidinone
- derivatives
- imidazopyrrolidinone derivatives
- Prior art date
Links
- LOROIKRUMJLRJU-UHFFFAOYSA-N 4,6-dihydro-1h-pyrrolo[2,3-d]imidazol-5-one Chemical class N1C=NC2=C1CC(=O)N2 LOROIKRUMJLRJU-UHFFFAOYSA-N 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13169390 | 2013-05-27 | ||
| EP13177676 | 2013-07-23 | ||
| PCT/IB2014/061715 WO2014191894A1 (en) | 2013-05-27 | 2014-05-26 | Imidazopyrrolidinone derivatives and their use in the treatment of disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015029491A2 true BR112015029491A2 (pt) | 2017-07-25 |
Family
ID=50979826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015029491A BR112015029491A2 (pt) | 2013-05-27 | 2014-05-26 | derivados de imidazopirrolidinona e seu uso no tratamento de doença |
Country Status (11)
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201506924YA (en) | 2013-03-15 | 2015-09-29 | Incyte Corp | Tricyclic heterocycles as bet protein inhibitors |
| CA2913697A1 (en) | 2013-05-27 | 2014-12-04 | Novartis Ag | Imidazopyrrolidinone derivatives and their use in the treatment of disease |
| CN105407888B (zh) | 2013-06-21 | 2019-05-21 | 齐尼思表观遗传学有限公司 | 新双环溴结构域抑制剂 |
| US9636328B2 (en) | 2013-06-21 | 2017-05-02 | Zenith Epigenetics Ltd. | Substituted bicyclic compounds as bromodomain inhibitors |
| US9290514B2 (en) | 2013-07-08 | 2016-03-22 | Incyte Holdings Corporation | Tricyclic heterocycles as BET protein inhibitors |
| CN105593224B (zh) | 2013-07-31 | 2021-05-25 | 恒元生物医药科技(苏州)有限公司 | 作为溴结构域抑制剂的新型喹唑啉酮类化合物 |
| LT3057586T (lt) | 2013-10-18 | 2020-03-10 | Celgene Quanticel Research, Inc. | Bromodomeno inhibitoriai |
| EA029269B1 (ru) * | 2013-11-21 | 2018-02-28 | Новартис Аг | Производные пирролопирролона и их применение для лечения заболеваний |
| WO2015081203A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| US9315501B2 (en) | 2013-11-26 | 2016-04-19 | Incyte Corporation | Bicyclic heterocycles as BET protein inhibitors |
| WO2015095492A1 (en) | 2013-12-19 | 2015-06-25 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
| TWI672301B (zh) | 2014-04-23 | 2019-09-21 | 美商英塞特公司 | 作為ＢＥＴ蛋白抑制劑之１Ｈ-吡咯并［２，３-ｃ］吡啶-７（６Ｈ）-酮及吡唑并［３，４-ｃ］吡啶-７（６Ｈ）-酮 |
| WO2016044130A1 (en) | 2014-09-15 | 2016-03-24 | Incyte Corporation | Tricyclic heterocycles for use as bet protein inhibitors |
| WO2016087942A1 (en) | 2014-12-01 | 2016-06-09 | Zenith Epigenetics Corp. | Substituted pyridines as bromodomain inhibitors |
| EP3227281A4 (en) | 2014-12-01 | 2018-05-30 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
| US10292968B2 (en) | 2014-12-11 | 2019-05-21 | Zenith Epigenetics Ltd. | Substituted heterocycles as bromodomain inhibitors |
| WO2016097863A1 (en) | 2014-12-17 | 2016-06-23 | Zenith Epigenetics Corp. | Inhibitors of bromodomains |
| GB201504694D0 (en) | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Covalent conjugates |
| AR104259A1 (es) | 2015-04-15 | 2017-07-05 | Celgene Quanticel Res Inc | Inhibidores de bromodominio |
| AR106520A1 (es) | 2015-10-29 | 2018-01-24 | Incyte Corp | Forma sólida amorfa de un inhibidor de proteína bet |
| CA3013988A1 (en) | 2016-02-15 | 2017-08-24 | Cemm-Forschungszentrum Fur Molekulare Medizin Gmbh | Taf1 inhibitors for the therapy of cancer |
| CN114369091A (zh) | 2016-06-20 | 2022-04-19 | 因赛特公司 | Bet抑制剂的结晶固体形式 |
| TW201822637A (zh) | 2016-11-07 | 2018-07-01 | 德商拜耳廠股份有限公司 | 用於控制動物害蟲的經取代磺醯胺類 |
| WO2018087401A2 (en) | 2016-11-14 | 2018-05-17 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Combination of a brd4 inhibitor and an antifolate for the therapy of cancer |
| EP3568392B1 (de) | 2017-01-10 | 2021-02-24 | Bayer Aktiengesellschaft | Imidazol-derivate als schädlingsbekämpfungsmittel |
| KR102628073B1 (ko) | 2017-01-10 | 2024-01-22 | 바이엘 악티엔게젤샤프트 | 해충 방제제로서의 헤테로사이클 유도체 |
| WO2018161871A1 (zh) * | 2017-03-06 | 2018-09-13 | 罗欣生物科技（上海）有限公司 | 作为p53-MDM2抑制剂的咪唑并吡咯酮化合物 |
| ES2942419T3 (es) * | 2017-03-31 | 2023-06-01 | Novartis Ag | Dosis y pauta para un inhibidor de la interacción HDM2-p53 en tumores hemáticos |
| WO2019067021A1 (en) * | 2017-09-28 | 2019-04-04 | The General Hospital Corporation | COMPOUNDS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH ABNORMAL STEROIDOGENESIS |
| JP2021512960A (ja) * | 2018-02-06 | 2021-05-20 | シャンハイ ハイファ ファーマシューティカル カンパニー，リミティッド | Ｂｅｔ阻害活性を有する化合物並びにその製造方法及び使用 |
| WO2019174576A1 (zh) * | 2018-03-12 | 2019-09-19 | 罗欣药业(上海)有限公司 | 咪唑并吡咯酮化合物及其应用 |
| TW202102492A (zh) * | 2019-03-15 | 2021-01-16 | 日商日本曹達股份有限公司 | 雜環化合物及農園藝用殺菌劑 |
| WO2021047466A1 (zh) * | 2019-09-12 | 2021-03-18 | 罗欣药业(上海)有限公司 | 一种p53-MDM2抑制剂的晶型及其制备方法 |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| WO2022002818A1 (de) | 2020-07-02 | 2022-01-06 | Bayer Aktiengesellschaft | Heterocyclen-derivate als schädlingsbekämpfungsmittel |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3829420A (en) | 1970-07-13 | 1974-08-13 | Sumitomo Chemical Co | 3,4-dihydro-2(1h)-quinazolinones and preparation thereof |
| US4099002A (en) | 1970-12-23 | 1978-07-04 | Sumitomo Chemical Company, Limited | Quinazolinone derivatives and a process for production thereof |
| JPS4822715B1 (enrdf_load_stackoverflow) | 1970-12-28 | 1973-07-07 | ||
| JPS5427356B2 (enrdf_load_stackoverflow) | 1972-03-31 | 1979-09-10 | ||
| US4258187A (en) | 1977-06-16 | 1981-03-24 | E. I. Du Pont De Nemours And Company | Process for preparing quinazolinone oxides |
| US4335127A (en) | 1979-01-08 | 1982-06-15 | Janssen Pharmaceutica, N.V. | Piperidinylalkyl quinazoline compounds, composition and method of use |
| JPS5721388A (en) | 1980-07-11 | 1982-02-04 | Nippon Nohyaku Co Ltd | Condensed pyrazole derivative |
| DE3420799A1 (de) | 1984-06-04 | 1985-12-05 | Bayer Ag, 5090 Leverkusen | Chromogene 4,4-diaryl-dihydrochinazolone, ihre herstellung und verwendung |
| AU2436792A (en) | 1991-08-16 | 1993-03-16 | Merck & Co., Inc. | Quinazoline derivatives as inhibitors of hiv reverse transcriptase |
| US5508300A (en) | 1994-01-14 | 1996-04-16 | Pfizer Inc. | Dihydro pyrazolopyrroles, compositions and use |
| PL180278B1 (pl) * | 1994-07-28 | 2001-01-31 | Byk Gulden Lomberg Chem Fab | Nowe imidazopirydyno-azolidynony, sposób ich wytwarzania oraz srodek farmaceutyczny PL PL PL PL PL PL PL |
| WO1998001467A2 (en) | 1996-07-05 | 1998-01-15 | Novartis Ag | Inhibitors of the interaction between p53 and mdm2 |
| DE69700594T2 (de) | 1996-10-28 | 2000-11-16 | Abb Power Systems Ab, Ludvika | Seewasser elektrode für ein hohe spannung gleichstrom-übertragungssystem |
| HRP980143A2 (en) | 1997-04-09 | 1999-02-28 | Soo Sung Ko | 4,4-disubstituted-3,4-dihydro-2 (1h)-quinazolinones useful as hiv reverse transcriptase inhibitors |
| WO2000066560A1 (en) | 1999-05-04 | 2000-11-09 | American Home Products Corporation | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators |
| JP2001302515A (ja) | 2000-04-18 | 2001-10-31 | Sumitomo Pharmaceut Co Ltd | ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤 |
| US6479499B1 (en) | 2000-06-28 | 2002-11-12 | National Science Council | 2-phenyl-4-quinazolinone compounds, 2-phenyl-4-alkoxy-quinazoline compounds and their pharmaceutical compositions |
| HU229824B1 (en) | 2000-08-10 | 2014-08-28 | Pfizer Italia Srl | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| AU2002366278B2 (en) | 2001-12-18 | 2007-07-19 | F. Hoffmann-La Roche Ag | CIS-2,4,5- triphenyl-imidazolines and their use in the treatment of tumors |
| AU2003214873A1 (en) | 2002-01-18 | 2003-09-02 | Ceretek Llc | Methods of treating conditions associated with an edg receptor |
| AU2003235504A1 (en) | 2002-05-13 | 2003-11-11 | 3-Dimensional Pharmaceuticals, Inc. | Method for cytoprotection through mdm2 and hdm2 inhibition |
| US7119111B2 (en) | 2002-05-29 | 2006-10-10 | Amgen, Inc. | 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use |
| WO2004014916A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Pyrimidine fused bicyclic metalloproteinase inhibitors |
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| US20040214856A1 (en) | 2003-04-23 | 2004-10-28 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| US20040213264A1 (en) | 2003-04-25 | 2004-10-28 | Nortel Networks Limited | Service class and destination dominance traffic management |
| CA2536313A1 (en) | 2003-08-22 | 2005-03-03 | Takeda Pharmaceutical Company Limited | Fused pyrimidine derivative and use thereof |
| JP2007533625A (ja) | 2003-09-22 | 2007-11-22 | バイオネットワークス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 炎症性及び／又は免疫媒介性の骨量減少の予防及び治療 |
| ES2376552T3 (es) | 2003-11-25 | 2012-03-14 | Novartis Ag | Compuestos de quinazolinona como agentes antic�?ncer. |
| WO2005110996A1 (en) | 2004-05-18 | 2005-11-24 | F.Hoffmann-La Roche Ag | Novel cis-imidazolines |
| BRPI0511748A (pt) | 2004-06-01 | 2008-01-02 | Univ Virginia | composição farmacêutica, métodos para tratar cáncer e uma doença ou distúrbio associado com angiogênese em um indivìduo em necessidade, para inibir a proliferação de células endoteliais vasculares e cancerosas, e para preparar sc-2-71 e análogos do mesmo, rótulo de fotoafinidade de sc-2-71, método para interromper a polimerização dos microtúbulos em uma célula, e para identificar um análogo, análogo, e, kit para administrar uma composiçaõ farmacêutica a um indivìduo |
| GB0419481D0 (en) | 2004-09-02 | 2004-10-06 | Cancer Rec Tech Ltd | Isoindolin-1-one derivatives |
| US20060069085A1 (en) | 2004-09-28 | 2006-03-30 | Rulin Zhao | Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones |
| JP2008526777A (ja) | 2005-01-05 | 2008-07-24 | ライジェル ファーマシューティカルズ， インコーポレイテッド | ユビキチンリガーゼインヒビター |
| EP1868685A2 (en) | 2005-03-18 | 2007-12-26 | onepharm GmbH | 11ß-HYDROXYSTEROID DEHYDROGENASES |
| AR056285A1 (es) | 2005-03-23 | 2007-10-03 | Syngenta Participations Ag | Derivados de triazolopirimidina y composiciones fungicidas |
| US7576082B2 (en) | 2005-06-24 | 2009-08-18 | Hoffman-La Roche Inc. | Oxindole derivatives |
| JP5222731B2 (ja) | 2005-12-12 | 2013-06-26 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | キナーゼ阻害薬として活性な置換ピロロ−ピラゾール誘導体 |
| WO2007096334A1 (en) | 2006-02-24 | 2007-08-30 | Pfizer Italia Srl | Pyrrolopyrrolones active as kinase inhibitors |
| DE102006016426A1 (de) | 2006-04-07 | 2007-10-11 | Merck Patent Gmbh | Neuartige Cyclobutyl-Verbindungen als Kinase-Inhibitoren |
| CA2655267A1 (en) | 2006-06-14 | 2007-12-21 | 4Sc Ag | Pyrazolopyrimidones |
| US8222288B2 (en) | 2006-08-30 | 2012-07-17 | The Regents Of The University Of Michigan | Small molecule inhibitors of MDM2 and the uses thereof |
| US8367699B2 (en) | 2006-09-15 | 2013-02-05 | Nexuspharma, Inc. | Tetrahydro-isoquinolines |
| WO2008045529A1 (en) | 2006-10-12 | 2008-04-17 | Serenex, Inc. | Purine and pyrimidine derivatives for treatment of cancer and inflammatory diseases |
| JP5624762B2 (ja) | 2007-03-30 | 2014-11-12 | 塩野義製薬株式会社 | 新規ピロリノン誘導体およびそれを含有する医薬組成物 |
| WO2008130614A2 (en) | 2007-04-20 | 2008-10-30 | University Of Pittsburg-Of The Commonwealth System Of Higher Education | Selective and dual-action p53/mdm2/mdm4 antagonists |
| CA2709784A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| UY31982A (es) | 2008-07-16 | 2010-02-26 | Boehringer Ingelheim Int | Derivados de 1,2-dihidropiridin-3-carboxamidas n-sustituidas |
| US8575197B2 (en) | 2008-09-25 | 2013-11-05 | Shionogi & Co., Ltd. | Pyrolinone derivative and pharmaceutical composition comprising the same |
| US8415386B2 (en) | 2008-10-08 | 2013-04-09 | Bristol-Myers Squibb Company | Azolopyrrolone melanin concentrating hormone receptor-1 antagonists |
| CN102292338B (zh) | 2008-12-08 | 2016-09-28 | 萌蒂制药国际有限公司 | 酪氨酸激酶蛋白受体拮抗剂 |
| WO2010075270A1 (en) | 2008-12-22 | 2010-07-01 | Incyte Corporation | 4, 6-disubstituted 2-amino-pyrimidines as histamine h4 receptor modulators |
| US20120208204A1 (en) | 2009-06-03 | 2012-08-16 | The Brigham And Women's Hospital, Inc. | Compositions and Methods for Inhibiting Tumor Growth |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| CU24130B1 (es) | 2009-12-22 | 2015-09-29 | Novartis Ag | Isoquinolinonas y quinazolinonas sustituidas |
| CN102199152A (zh) * | 2010-03-25 | 2011-09-28 | 高大新 | 杂环咪唑类磷脂激酶抑制剂 |
| ES2526671T3 (es) | 2010-06-22 | 2015-01-14 | Glaxosmithkline Llc | Compuestos de benzotriazoldiazepina inhibidores de bromodominios |
| US9133186B2 (en) * | 2010-09-10 | 2015-09-15 | Shionogi & Co., Ltd. | Hetero ring-fused imidazole derivative having AMPK activating effect |
| US20120065210A1 (en) | 2010-09-15 | 2012-03-15 | Xin-Jie Chu | Substituted hexahydropyrrolo[1,2-c]imidazolones |
| GB201016880D0 (en) | 2010-10-07 | 2010-11-17 | Riotech Pharmaceuticals Ltd | Phosphodiesterase inhibitors |
| CA2817585A1 (en) | 2010-11-12 | 2012-05-18 | The Regents Of The University Of Michigan | Spiro-oxindole mdm2 antagonists |
| US9422292B2 (en) | 2011-05-04 | 2016-08-23 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| EP2721031B1 (en) | 2011-06-17 | 2016-01-20 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| EP2721007B1 (en) | 2011-06-20 | 2015-04-29 | Novartis AG | Cyclohexyl isoquinolinone compounds |
| WO2012175520A1 (en) | 2011-06-20 | 2012-12-27 | Novartis Ag | Hydroxy substituted isoquinolinone derivatives |
| WO2013027168A1 (en) | 2011-08-22 | 2013-02-28 | Pfizer Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
| WO2013033270A2 (en) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bromodomain ligands capable of dimerizing in an aqueous solution, and methods of using same |
| EP2785717B1 (en) | 2011-11-29 | 2016-01-13 | Novartis AG | Pyrazolopyrrolidine compounds |
| WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| JO3357B1 (ar) * | 2012-01-26 | 2019-03-13 | Novartis Ag | مركبات إيميدازوبيروليدينون |
| US20130281399A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| US20130281397A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| US20130281396A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| EP2838881B1 (en) | 2012-04-20 | 2018-08-08 | AbbVie Inc. | Isoindolone derivatives |
| CN104321325B (zh) | 2012-05-24 | 2016-11-16 | 诺华股份有限公司 | 吡咯并吡咯烷酮化合物 |
| CA2913697A1 (en) | 2013-05-27 | 2014-12-04 | Novartis Ag | Imidazopyrrolidinone derivatives and their use in the treatment of disease |
-
2014
- 2014-05-26 CA CA2913697A patent/CA2913697A1/en not_active Abandoned
- 2014-05-26 EP EP14731798.6A patent/EP3004109A1/en not_active Withdrawn
- 2014-05-26 US US14/892,616 patent/US9890166B2/en not_active Expired - Fee Related
- 2014-05-26 JP JP2016516276A patent/JP6373978B2/ja not_active Expired - Fee Related
- 2014-05-26 AU AU2014272774A patent/AU2014272774B2/en not_active Ceased
- 2014-05-26 EA EA201592256A patent/EA029312B1/ru not_active IP Right Cessation
- 2014-05-26 CN CN201480028176.6A patent/CN105209467B/zh not_active Expired - Fee Related
- 2014-05-26 MX MX2015016344A patent/MX2015016344A/es unknown
- 2014-05-26 WO PCT/IB2014/061715 patent/WO2014191894A1/en active Application Filing
- 2014-05-26 BR BR112015029491A patent/BR112015029491A2/pt active Search and Examination
- 2014-05-26 KR KR1020157036223A patent/KR20160012194A/ko not_active Withdrawn
- 2014-05-26 EP EP18173244.7A patent/EP3412675A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014272774A1 (en) | 2015-11-26 |
| CA2913697A1 (en) | 2014-12-04 |
| MX2015016344A (es) | 2016-03-01 |
| EP3412675A1 (en) | 2018-12-12 |
| JP2016520116A (ja) | 2016-07-11 |
| US20160108047A1 (en) | 2016-04-21 |
| CN105209467A (zh) | 2015-12-30 |
| EA029312B1 (ru) | 2018-03-30 |
| KR20160012194A (ko) | 2016-02-02 |
| CN105209467B (zh) | 2018-06-08 |
| AU2014272774B2 (en) | 2016-12-08 |
| US9890166B2 (en) | 2018-02-13 |
| JP6373978B2 (ja) | 2018-08-15 |
| EA201592256A1 (ru) | 2016-04-29 |
| EP3004109A1 (en) | 2016-04-13 |
| WO2014191894A1 (en) | 2014-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| BR112015029512A8 (pt) | derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas | |
| BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
| BR112015016911A2 (pt) | tiadiazol, análogos dos mesmos e métodos de tratamento de condições relacionadas à deficiência de smn | |
| BR112014032734A2 (pt) | derivados de pirrolidina e seu uso como moduladores da série de reação de complemento | |
| BR112015029353A2 (pt) | derivados de pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças | |
| EA201590371A1 (ru) | 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний | |
| BR112015003188A2 (pt) | Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
| BR112013026257A2 (pt) | derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes | |
| BR112015018252A2 (pt) | composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit | |
| BR112015007366A2 (pt) | derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças | |
| BR112019005318A2 (pt) | compostos de aza-indazol para uso em lesões no tendão e/ou ligamento | |
| BR112015019369A2 (pt) | derivados de ácido bisfenil butanóico substituídos como inibidores de nep (endopeptidase neutra) | |
| BR112015009504A2 (pt) | inibidores de rock | |
| BR112018070536A2 (pt) | composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição | |
| EA201691058A1 (ru) | Производные пирролопирролона и их применение для лечения заболеваний | |
| BR112015014433A2 (pt) | compostos tricíclicos | |
| BR112013026361A2 (pt) | derivados de glicosídeo e usos dos mesmos | |
| BR112012020377A8 (pt) | utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial | |
| BR112018070514A2 (pt) | composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição | |
| BR112014004732A2 (pt) | composto benzotiazolona | |
| EA201591653A1 (ru) | Композиции для лечения глазных расстройств с применением дипиридамола | |
| BR112015013414A2 (pt) | derivados de naftiridona e seu uso no tratamento, melhora ou prevenção de uma doença viral | |
| BR112019024804A2 (pt) | compostos bicíclicos 5,6-fundidos e composições para o tratamento de doenças parasíticas | |
| BR112014030288A8 (pt) | composição farmacêutica, uso da mesma, e, uso de metanossulfonilacetonitrila |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |